Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Formulary product proposals should include three-year cost-impact assessments.

Executive Summary

FORMULARY LISTED PRODUCTS SHOULD HAVE THREE-YEAR COST-IMPACT ASSESSMENTS, according to pharmacoeconomic guidelines for managed care organizations developed by Paul Langley, PhD, University of Arizona-Tuscon, and Sean Sullivan, PhD, University of Washington-Seattle. The guidelines are published in the November/December issue of the Academy of Managed Care Pharmacy's Journal of Managed Care Pharmacy.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS029172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel